• 中國(guó)醫(yī)科大學(xué)附屬第一醫(yī)院普通外科教研室(沈陽(yáng) 110001);

引用本文： 劉煒煒,葛春林. Castleman病. 中國(guó)普外基礎(chǔ)與臨床雜志, 2010, 17(8): 868-871. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma [J]. Cancer, 1956; 9(4): 822830.
2. Keller AR, Hochholzer L, Castleman B. Hyalinevascular and plasmacell types of giant lymph node hyperplasia of the mediastinum and other locations [J]. Cancer, 1972; 29(3): 670683.
3. Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia [J]. Am J Clin Pathol, 1978; 69(1): 8690.
4. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature [J]. Cancer, 1999; 85(3): 706717.
5. Dispenzieri A. Castleman disease [J]. Cancer Treat Res, 2008; 142: 293330.
6. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions [J]. Adv Anat Pathol, 2009; 16(4): 236246.
7. Wang H, Wieczorek RL, Zenilman ME, et al. Castleman’s disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome [J]. World J Surg Oncol, 2007; 5: 133.
8. Kojima M, Nakamura S, Miyawaki S, et al. Progressive transformation of germinal center presenting with histological features of hyalinevascular type of Castleman’s disease [J]. APMIS, 2005; 113(4): 288295.
9. Roca B. Castleman’s disease. A review [J]. AIDS Rev, 2009; 11(1): 37.
10. McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders [J]. Hematology Am Soc Hematol Educ Program, 2004; 283296.
11. Hsu SM, Waldron JA, Xie SS, et al. Expression of interleukin6 in Castleman’s disease [J]. Hum Pathol, 1993; 24(8): 833839.
12. Bucher P, Chassot G, Zufferey G, et al. Surgical management of abdominal and retroperitoneal Castleman’s disease [J]. World J Surg Oncol, 2005; 3: 33.
13. Dispenzieri A, Gertz MA. Treatment of Castleman’s disease [J]. Curr Treat Options Oncol, 2005; 6(3): 255266.
14. Chan AC, Chan KW, Chan JK, et al. Development of follicular dendritic cell sarcoma in hyalinevascular Castleman’s disease of the nasopharynx: tracing its evolution by sequential biopsies [J]. Histopathology, 2001; 38(6): 510518.
15. Waterston A, Bower M. Fifty years of multicentric Castleman’s disease [J]. Acta Oncol, 2004; 43(8): 698704.
16. 黃小兵, 李靖, 梁平, 等. 腹膜后血管濾泡增生癥的診斷治療(附3例報(bào)道) [J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2005; 12(1): 7980.
17. Fields S, BarZiv J, Portnoy O, et al. Radiologic spectrum of localized Castleman’s disease [J]. Isr J Med Sci, 1995; 31(11): 660669.
18. Takihara H, Yamakawa G, Baba Y, et al. Castleman disease. Unusual retroperitoneal location indistinguishable from malignant tumor in preoperative angiographic appearance [J]. Urology, 1993; 41(2): 162164.
19. Murphy SP, Nathan MA, Karwal MW. FDGPET appearance of pelvic Castleman’s disease [J]. J Nucl Med, 1997; 38(8): 12111212.
20. Enomoto K, Nakamichi I, Hamada K, et al. Unicentric and multicentric Castleman’s disease [J]. Br J Radiol, 2007; 80(949): e24e26.
21. Oida Y, Shimizu K, Mukai M, et al. FDGPET and diffusionweighted MR imaging appearance in retroperitoneal Castleman’s disease: a case report [J]. Clin Imaging, 2008; 32(2): 144146.
22. Halac M, Ergul N, Sager S, et al. PET/CT findings in a multicentric form of Castleman’s disease [J]. Hell J Nucl Med, 2007; 10(3): 172174.
23. Frizzera G. Castleman’s disease and related disorders [J]. Semin Diagn Pathol, 1988; 5(4): 346364.
24. Maruyama S, Hao N, Cheng J, et al. Castleman’s disease of the buccal mucosa: report of a case and review of the literature of head and neck cases [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2002; 93(3): 305310.
25. Weisenburger DD, Nathwani BN, Winberg CD, et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases [J]. Hum Pathol, 1985; 16(2): 162172.
26. Shahidi H, Myers JL, Kvale PA. Castleman’s disease [J]. Mayo Clin Proc, 1995; 70(10): 969977.
27. Kiguchi H, Ishii T, Ishikawa Y, et al. Castleman’s disease of the abdomen and pelvis: report of three cases and a review of the literature [J]. J Gastroenterol, 1995; 30(5): 661666.
28. 羅友軍. 腹膜后Castleman病1例報(bào)告 [J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2005; 12(3): 279.
29. Dham A, Peterson BA. Castleman disease [J]. Curr Opin Hematol, 2007; 14(4): 354359.
30. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapydependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial [J]. J Clin Oncol, 2007; 25(22): 33503356.
31. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIVassociated multicentric Castleman disease [J]. Ann Intern Med, 2007; 147(12): 836839.
32. Seliem RM, Griffith RC, Harris NL, et al. HHV8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ Man: the spectrum of HHV8+ lymphoproliferative disorders expands [J]. Am J Surg Pathol, 2007; 31(9): 14391445.
33. Simonelli C, Tedeschi R, Gloghini A, et al. Plasma HHV8 viral load in HHV8related lymphoproliferative disorders associated with HIV infection [J]. J Med Virol, 2009; 81(5): 888896.
34. Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV8specific CD8+ T cells [J]. Blood, 2008; 111(3): 13871395.
35. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin6 (IL6) and soluble IL6 receptor after administration of an antiIL6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease [J]. Blood, 2008; 112(10): 39593964.
36. Menke DM, Chadbum A, Cesarman E, et al. Analysis of the human herpesvirus 8 (HHV8) genome and HHV8 vIL6 expression in archival cases of castleman disease at low risk for HIV infection [J]. Am J Clin Pathol, 2002; 117(2): 268275.
37. Matsuyama M, Suzuki T, Tsuboi H, et al. Antiinterleukin6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease [J]. Intern Med, 2007; 46(11): 771774.
38. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIVassociated multicentric Castleman’s disease with oral etoposide [J]. Am J Hematol, 2001; 66(2): 148150.
39. Kumari P, Schechter GP, Saini N, et al. Successful treatment of human immunodeficiency virusrelated Castleman’s disease with interferonα [J]. Clin Infect Dis, 2000; 31(2): 602604.
  1. 1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma [J]. Cancer, 1956; 9(4): 822830.
  2. 2. Keller AR, Hochholzer L, Castleman B. Hyalinevascular and plasmacell types of giant lymph node hyperplasia of the mediastinum and other locations [J]. Cancer, 1972; 29(3): 670683.
  3. 3. Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia [J]. Am J Clin Pathol, 1978; 69(1): 8690.
  4. 4. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature [J]. Cancer, 1999; 85(3): 706717.
  5. 5. Dispenzieri A. Castleman disease [J]. Cancer Treat Res, 2008; 142: 293330.
  6. 6. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions [J]. Adv Anat Pathol, 2009; 16(4): 236246.
  7. 7. Wang H, Wieczorek RL, Zenilman ME, et al. Castleman’s disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome [J]. World J Surg Oncol, 2007; 5: 133.
  8. 8. Kojima M, Nakamura S, Miyawaki S, et al. Progressive transformation of germinal center presenting with histological features of hyalinevascular type of Castleman’s disease [J]. APMIS, 2005; 113(4): 288295.
  9. 9. Roca B. Castleman’s disease. A review [J]. AIDS Rev, 2009; 11(1): 37.
  10. 10. McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders [J]. Hematology Am Soc Hematol Educ Program, 2004; 283296.
  11. 11. Hsu SM, Waldron JA, Xie SS, et al. Expression of interleukin6 in Castleman’s disease [J]. Hum Pathol, 1993; 24(8): 833839.
  12. 12. Bucher P, Chassot G, Zufferey G, et al. Surgical management of abdominal and retroperitoneal Castleman’s disease [J]. World J Surg Oncol, 2005; 3: 33.
  13. 13. Dispenzieri A, Gertz MA. Treatment of Castleman’s disease [J]. Curr Treat Options Oncol, 2005; 6(3): 255266.
  14. 14. Chan AC, Chan KW, Chan JK, et al. Development of follicular dendritic cell sarcoma in hyalinevascular Castleman’s disease of the nasopharynx: tracing its evolution by sequential biopsies [J]. Histopathology, 2001; 38(6): 510518.
  15. 15. Waterston A, Bower M. Fifty years of multicentric Castleman’s disease [J]. Acta Oncol, 2004; 43(8): 698704.
  16. 16. 黃小兵, 李靖, 梁平, 等. 腹膜后血管濾泡增生癥的診斷治療(附3例報(bào)道) [J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2005; 12(1): 7980.
  17. 17. Fields S, BarZiv J, Portnoy O, et al. Radiologic spectrum of localized Castleman’s disease [J]. Isr J Med Sci, 1995; 31(11): 660669.
  18. 18. Takihara H, Yamakawa G, Baba Y, et al. Castleman disease. Unusual retroperitoneal location indistinguishable from malignant tumor in preoperative angiographic appearance [J]. Urology, 1993; 41(2): 162164.
  19. 19. Murphy SP, Nathan MA, Karwal MW. FDGPET appearance of pelvic Castleman’s disease [J]. J Nucl Med, 1997; 38(8): 12111212.
  20. 20. Enomoto K, Nakamichi I, Hamada K, et al. Unicentric and multicentric Castleman’s disease [J]. Br J Radiol, 2007; 80(949): e24e26.
  21. 21. Oida Y, Shimizu K, Mukai M, et al. FDGPET and diffusionweighted MR imaging appearance in retroperitoneal Castleman’s disease: a case report [J]. Clin Imaging, 2008; 32(2): 144146.
  22. 22. Halac M, Ergul N, Sager S, et al. PET/CT findings in a multicentric form of Castleman’s disease [J]. Hell J Nucl Med, 2007; 10(3): 172174.
  23. 23. Frizzera G. Castleman’s disease and related disorders [J]. Semin Diagn Pathol, 1988; 5(4): 346364.
  24. 24. Maruyama S, Hao N, Cheng J, et al. Castleman’s disease of the buccal mucosa: report of a case and review of the literature of head and neck cases [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2002; 93(3): 305310.
  25. 25. Weisenburger DD, Nathwani BN, Winberg CD, et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases [J]. Hum Pathol, 1985; 16(2): 162172.
  26. 26. Shahidi H, Myers JL, Kvale PA. Castleman’s disease [J]. Mayo Clin Proc, 1995; 70(10): 969977.
  27. 27. Kiguchi H, Ishii T, Ishikawa Y, et al. Castleman’s disease of the abdomen and pelvis: report of three cases and a review of the literature [J]. J Gastroenterol, 1995; 30(5): 661666.
  28. 28. 羅友軍. 腹膜后Castleman病1例報(bào)告 [J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2005; 12(3): 279.
  29. 29. Dham A, Peterson BA. Castleman disease [J]. Curr Opin Hematol, 2007; 14(4): 354359.
  30. 30. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapydependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial [J]. J Clin Oncol, 2007; 25(22): 33503356.
  31. 31. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIVassociated multicentric Castleman disease [J]. Ann Intern Med, 2007; 147(12): 836839.
  32. 32. Seliem RM, Griffith RC, Harris NL, et al. HHV8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ Man: the spectrum of HHV8+ lymphoproliferative disorders expands [J]. Am J Surg Pathol, 2007; 31(9): 14391445.
  33. 33. Simonelli C, Tedeschi R, Gloghini A, et al. Plasma HHV8 viral load in HHV8related lymphoproliferative disorders associated with HIV infection [J]. J Med Virol, 2009; 81(5): 888896.
  34. 34. Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV8specific CD8+ T cells [J]. Blood, 2008; 111(3): 13871395.
  35. 35. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin6 (IL6) and soluble IL6 receptor after administration of an antiIL6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease [J]. Blood, 2008; 112(10): 39593964.
  36. 36. Menke DM, Chadbum A, Cesarman E, et al. Analysis of the human herpesvirus 8 (HHV8) genome and HHV8 vIL6 expression in archival cases of castleman disease at low risk for HIV infection [J]. Am J Clin Pathol, 2002; 117(2): 268275.
  37. 37. Matsuyama M, Suzuki T, Tsuboi H, et al. Antiinterleukin6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease [J]. Intern Med, 2007; 46(11): 771774.
  38. 38. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIVassociated multicentric Castleman’s disease with oral etoposide [J]. Am J Hematol, 2001; 66(2): 148150.
  39. 39. Kumari P, Schechter GP, Saini N, et al. Successful treatment of human immunodeficiency virusrelated Castleman’s disease with interferonα [J]. Clin Infect Dis, 2000; 31(2): 602604.